A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Eli Lilly and Company
Eli Lilly and Company
Dana-Farber Cancer Institute
Ohio State University Comprehensive Cancer Center
Case Comprehensive Cancer Center
Thomas Jefferson University
Incyte Corporation
Dana-Farber Cancer Institute
Austin Health
Innovent Biologics (Suzhou) Co. Ltd.
Washington University School of Medicine
Fate Therapeutics
University of Washington
MEI Pharma, Inc.
Brown University
Ohio State University Comprehensive Cancer Center
SymBio Pharmaceuticals
University of Washington
Celgene
Pfizer
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Swiss Cancer Institute
Boehringer Ingelheim
Wake Forest University Health Sciences
UNC Lineberger Comprehensive Cancer Center
Aptevo Therapeutics
UNC Lineberger Comprehensive Cancer Center
Hoffmann-La Roche
Case Comprehensive Cancer Center
City of Hope Medical Center
University of California, San Francisco
CTI BioPharma
National Cancer Institute (NCI)
University of Alabama at Birmingham
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northwestern University
National Institutes of Health Clinical Center (CC)
Mayo Clinic
City of Hope Medical Center